高危MDS药物开发的困境:近期失败III期临床试验的经验教训
除异基因移植外,高危骨髓增生异常综合征/肿瘤(HR-MDS)的标准治疗仍为去甲基化药物(HMA)单药,包括阿扎胞苷、地西他滨或口服地西他滨/西达尿苷。许多基于HMA的联合方案未能超越HMA单药。尽管多种药物在早期临床试验中显示出有希望的疗效,但随后的随机III期试验未能证实完全缓解率或总生存期的改善。本文综述了近期阿扎胞苷联合eprenetapopt(APR-246)、magrolimab、pevonedistat、sabatolimab、tamibarotene和venetoclax的阴性试验的经验教训,并提出应强调生物学分类而非仅疾病风险状态来选择HR-MDS试验患者、TP53失活MDS和慢性粒单核细胞白血病应在专门临床试验中治疗、若TP53失活MDS纳入HR-MDS试验则随机化分层应考虑TP53失活状态、不应忽视早期试验中观察到的过度毒性和研究药物过早停用的信号、国际工作组(IWG)2006疗效标准可能高估和低估真实治疗获益而应使用IWG 2023疗效标准、科学界需要高效快速获取失败III期试验的患者水平数据和样本。
要点
- HR-MDS标准治疗仍为HMA单药,多种HMA联合方案在III期试验中未能改善完全缓解率或总生存期。
- 选择HR-MDS试验患者应强调生物学分类而非仅疾病风险状态。
- TP53失活MDS和慢性粒单核细胞白血病应在专门临床试验中治疗。
核心结论
- 除异基因移植外,HR-MDS的标准治疗仍为HMA单药,包括阿扎胞苷、地西他滨或口服地西他滨/西达尿苷。
- 许多基于HMA的联合方案未能超越HMA单药,近期随机III期试验未能证实完全缓解率或总生存期的改善。
研究设计与样本
- 本文为综述,讨论了近期阿扎胞苷联合eprenetapopt(APR-246)、magrolimab、pevonedistat、sabatolimab、tamibarotene和venetoclax的阴性III期试验。
主要发现
- 多种药物在早期临床试验中显示出有希望的疗效,但随后的随机III期试验未能证实完全缓解率或总生存期的改善。
- IWG 2006疗效标准长期用于HR-MDS试验,可能高估和低估真实治疗获益。
关键数值与推荐
- 应强调生物学分类而非仅疾病风险状态来选择HR-MDS试验患者。
- TP53失活MDS和慢性粒单核细胞白血病应在专门临床试验中治疗。
- 若TP53失活MDS纳入HR-MDS试验,随机化分层应考虑TP53失活状态。
- 不应忽视早期试验中观察到的过度毒性和研究药物过早停用的信号。
- 应使用IWG 2023疗效标准以更好地捕捉HR-MDS中有临床意义的获益。
临床怎么用
- 作者认为应强调生物学分类而非仅疾病风险状态来选择HR-MDS试验患者。
- 作者认为TP53失活MDS和慢性粒单核细胞白血病应在专门临床试验中治疗。
- 作者认为若TP53失活MDS纳入HR-MDS试验,随机化分层应考虑TP53失活状态。
- 作者提醒不应忽视早期试验中观察到的过度毒性和研究药物过早停用的信号。
- 作者提倡使用IWG 2023疗效标准以更好地捕捉HR-MDS中有临床意义的获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts using HMA-based combinations have failed to improve upon HMA monotherapy. Although promising efficacy was observed in early-phase clinical trials with several agents, subsequent randomized phase 3 trials failed to confirm improvements in complete response rates or overall survival. In this review, we discuss lessons learned from the recently reported negative trials of azacitidine in combination with eprenetapopt (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax. First, we make a case for emphasizing biological classification rather than disease risk status alone to select patients for HR-MDS trials. Second, we argue that patients with TP53-inactivated MDS and chronic myelomonocytic leukemia should be treated in dedicated clinical trials. Alternatively, if TP53-inactivated MDS is included in HR-MDS trials, then randomization stratification by TP53 inactivation status should be considered. Third, we caution against ignoring signals of excessive toxicity and premature discontinuation of investigational agent observed in early-phase trials. Fourth, we show that the International Working Group (IWG) 2006 response criteria, long used in HR-MDS trials, can both overestimate and underestimate the true therapeutic benefit. Instead, we advocate for using the IWG 2023 response criteria to better capture clinically meaningful benefits in HR-MDS. Lastly, we emphasize the need for the scientific community to access patient-level data and samples from failed phase 3 trials in an efficient and expedited fashion to inform the development of subsequent trials.
引用
- Stahl M, Zeidan AM. The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. Blood. 2026. PMID: 41175364. doi:10.1182/blood.2025029727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。